These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38181624)

  • 1. A fluorescence chemo sensor approach for determination of finerenone in pharmaceutical formulation and human plasma: Method development and validation.
    Alsharif ST; Alaqel SL; Almalki AH; Algarni MA; Alnemari RM; H Abduljabbar M; Abdelazim AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Mar; 309():123836. PubMed ID: 38181624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of finerenone - a novel, selective, nonsteroidal mineralocorticoid receptor antagonist - in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma.
    Rohde G; Loewen S; Heinig R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1172():122643. PubMed ID: 33770684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of fluorescence chemo sensor for selective histamine determination in spiked human plasma samples.
    Alqahtani A; Alqahtani T; Abdelazim AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Mar; 308():123711. PubMed ID: 38042122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
    Beavers CJ
    Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
    Lerma EV; Wilson DJ
    Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
    Gerisch M; Heinig R; Engelen A; Lang D; Kolkhof P; Radtke M; Platzek J; Lovis K; Rohde G; Schwarz T
    Drug Metab Dispos; 2018 Nov; 46(11):1546-1555. PubMed ID: 30171161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
    J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
    Doggrell SA
    Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
    Ravid JD; Laffin LJ
    Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
    Verma A; Patel AB
    Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finerenone: First Approval.
    Frampton JE
    Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
    Lentini S; Heinig R; Kimmeskamp-Kirschbaum N; Wensing G
    Fundam Clin Pharmacol; 2016 Apr; 30(2):172-84. PubMed ID: 26604072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
    Lachaux M; Barrera-Chimal J; Nicol L; Rémy-Jouet I; Renet S; Dumesnil A; Wecker D; Richard V; Kolkhof P; Jaisser F; Ouvrard-Pascaud A; Mulder P
    Diabetes Obes Metab; 2018 Oct; 20(10):2399-2407. PubMed ID: 29862614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
    Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
    N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.